Literature DB >> 23252905

The myasthenia gravis--specific activities of daily living profile.

Srikanth Muppidi1.   

Abstract

The myasthenia gravis activities of daily living (MG-ADL) profile is an eight-item patient-reported scale developed to assess MG symptoms and their effects on daily activities. The MG-ADL profile correlated well with the Quantitative MG (QMG) score (r= 0.58, P < 0.001) in 254 consecutive patient visits. Further analysis during clinical trials confirmed the excellent correlation with the QMG test and provided additional evidence that the MG-ADL profile is responsive to clinical improvement. MG-ADL performance was further analyzed during a recent multicenter, prospective scale validation study for two new outcome measures. At the first visit, there was a strong positive correlation between the MG-ADL and the MG Composite (r= 0.85, P < 0.0001) and between the MG-ADL and the MG-Quality of life15 (MG-QOL15) (r= 0.76, P < 0.0001). Test-retest analysis demonstrated a high reliability coefficient. Sensitivity/specificity analysis revealed that a 2-point improvement has the best trade-off attributes to predict clinical improvement. The MG-ADL profile also performed well on Rasch analysis. The MG-ADL scoring system is useful as a secondary outcome measure and in routine clinical management.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Year:  2012        PMID: 23252905     DOI: 10.1111/j.1749-6632.2012.06817.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  18 in total

1.  Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.

Authors:  Alberto Raggi; Carlo Antozzi; Fulvio Baggi; Matilde Leonardi; Lorenzo Maggi; Renato Mantegazza
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

Review 2.  Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis.

Authors:  Olivia Tong; Leslie Delfiner; Steven Herskovitz
Journal:  Curr Pain Headache Rep       Date:  2018-05-03

3.  Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.

Authors:  David Cioncoloni; Stefania Casali; Federica Ginanneschi; Marisa Carone; Boni Veronica; Alessandro Rossi; Fabio Giannini
Journal:  Neurol Sci       Date:  2016-04-01       Impact factor: 3.307

4.  A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Authors:  Mamatha Pasnoor; Jianghua He; Laura Herbelin; Ted M Burns; Sharon Nations; Vera Bril; Annabel K Wang; Bakri H Elsheikh; John T Kissel; David Saperstein; J Aziz Shaibani; Carlayne Jackson; Andrea Swenson; James F Howard; Namita Goyal; William David; Matthew Wicklund; Michael Pulley; Mara Becker; Tahseen Mozaffar; Michael Benatar; Robert Pazcuzzi; Ericka Simpson; Jeffrey Rosenfeld; Mazen M Dimachkie; Jeffrey M Statland; Richard J Barohn
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

5.  Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.

Authors:  Rui Zhao; Ying Wang; Xiao Huan; Huahua Zhong; Zhirui Zhou; Jianying Xi; Yuwei Da; Lin Lei; Ting Chang; Zhe Ruan; Lijun Luo; Shengnan Li; Huan Yang; Yi Li; Sushan Luo; Chongbo Zhao
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531

6.  Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).

Authors:  Srikanth Muppidi; Richard J Nowak; Amanda C Guidon; Jeffrey T Guptill; Michael K Hehir; Katherine Ruzhansky; Leeann B Burton; David Post; Gary Cutter; Robin Conwit; Nicte I Mejia; Henry J Kaminski; James F Howard
Journal:  Muscle Nerve       Date:  2021-07-07       Impact factor: 3.852

Review 7.  Eculizumab: A Review in Generalized Myasthenia Gravis.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546

Review 8.  Understanding the burden of refractory myasthenia gravis.

Authors:  Christiane Schneider-Gold; Tim Hagenacker; Nico Melzer; Tobias Ruck
Journal:  Ther Adv Neurol Disord       Date:  2019-03-01       Impact factor: 6.570

9.  Eculizumab improves fatigue in refractory generalized myasthenia gravis.

Authors:  Henning Andersen; Renato Mantegazza; Jing Jing Wang; Fanny O'Brien; Kaushik Patra; James F Howard
Journal:  Qual Life Res       Date:  2019-03-23       Impact factor: 4.147

10.  Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.

Authors:  James F Howard; Chafic Karam; Marcus Yountz; Fanny L O'Brien; Tahseen Mozaffar
Journal:  Ann Clin Transl Neurol       Date:  2021-05-27       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.